PARP-inhibitor study opens for BRCA+, HER2- breast cancer

October 01, 2018

A new study of the PARP inhibitor niraparib for women with localized, HER2-negative, BRCA-mutant breast cancer is now open at Providence Cancer Institute.

In women with the BRCA1 and BRCA2 gene mutations, an important DNA-repair pathway becomes damaged. Cancer cells can survive without this pathway, but when an alternate DNA-repair pathway also is blocked by the introduction of a PARP inhibitor, cancer cells die. This is why “the development of PARP inhibitors has become one of the promising breakthroughs and hot spots in the area of experimental oncology.” (Gynecologic Oncology Research and Practice, Nov. 2017.) Niraparib is the first drug in its class to receive global approval as maintenance therapy for recurrent gynecologic cancers, regardless of a woman’s BRCA or HRD status.

 

Get study details here:
An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients

Medical Oncologist David Page, M.D., leads the study for Providence.

Read more about PARP inhibitors for BRCA-mutant breast cancer in OncLive.

For more information about this study, or to enroll a patient, call our Clinical Research office at 503-215-2614.

See more breast cancer studies
This study is one of 22 ongoing research studies investigating a broad spectrum of breast cancer therapies and interventions at Providence Cancer Institute. We offer studies aimed at improving cure rates, quality of life and survival for both early-stage and metastatic breast cancer patients. These studies range from small phase I clinical trials to larger international studies, including studies from the National Cancer Institute, our own NCI Community Oncology Research Program (the Pacific Cancer Research Consortium), and pharmaceutical industry partners. Our own investigator-initiated research studies, available exclusively at Providence Cancer Institute, focus on novel approaches that harness the immune system to treat cancer.

New research studies are added frequently. Please visit our website to see all breast cancer studies currently open at Providence Cancer Institute.

A team of breast cancer specialists
The research team at the Earle A. Chiles Research Institute at Providence Cancer Institute includes oncologists who specialize exclusively in breast cancer, as well as breast-cancer-focused research nurses, laboratory scientists, data coordinators and lab assistants. Every person on this team is passionate about providing the best possible care and the best available study options for patients with breast cancer.